CORONA is the second fastest growing company, amongst the top 30 companies in IPM, in terms of domestic sales MAT DEC ’24. CORONA registered a CAGR of 20%, displaying a growth of more than 2.25 times of IPM growth. (IPM CAGR – 8.79% for the period) 

CORONA has a key focus on Women’s healthcare, Cardio-diabeto, Pain Management, Urology, and other therapeutic areas. CORONA enjoys a leadership position with rank #6 in women’s healthcare, rank #5 in pain management, rank #11 in urology and #21 in cardio-diabeto in addressable market.

Our success is a result of differentiator strategy of focusing on the middle of the pyramid market segment, with strong hold on specialists and super-specialist doctors and strategical presence of marketing and distribution personnel in urban and semi-urban areas.  

CORONA has two manufacturing facilities located in the states of Gujarat and Himachal Pradesh. We are in the process of establishing a hormone manufacturing facility in Gujarat.  

CORONA has 11 production lines and is able to handle complex manufacturing processes, with various drug delivery systems.  

Our manufacturing facility is spread over an aggregate of 2.83 hectares.  

We are focused on process excellence and quality with our manufacturing facilities based in Gujarat, producing oral solids, being EU-GMP and WHO certified, while other manufacturing facility at Himachal Pradesh producing oral solids, being WHO-GMP certified.